Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Ionis has a long-standing reputation for being science driven, but in its 30-year history the company had never told its own story—until now.
Purdue took a big hit when it settled with Oklahoma over claims it misleadingly advertised its powerful opioid, OxyContin. Now more states want in.
Discover why Samsung BioLogics is uniquely positioned as a global leader to help companies stay agile and competitive in a rapidly expanding biopharmaceutical…
Celltrion Chairman Seo Jung-jin says the South Korean company will spend about $33 billion over a decade on its biologics and pharma businesses.
Gilead's Truvada for PrEP is only getting to about 10% of people who could benefit, according to testimony Thursday.
The new endorsement of Celgene's Revlimid from England's cost watchdog NICE may not help calm fears about BMS' $74 billion buyout.
EMS Pharma, whose sister company Novamed bought Takeda’s Multilab last year, is reportedly the front-runner in the bidding process.
Takeda releases first post-Shire guidance; Indian generics makers are named in a price-fixing suit; Daiichi's quizartinib fails at FDA.
Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun, Mexico.
Since Nestlé took full control of Galderma in 2014, its skin health unit never really lived up to expectations. And now, the company is bailing.
GlaxoSmithKline will unload an API plant to Thermo Fisher Scientific for €90 million. The U.S. company says it is glad to get it.